IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) (KALMAR)
This study has been terminated.
(Poor enrollment)
Sponsor:
Temple University
Collaborators:
Abbott
Pfizer
Information provided by (Responsible Party):
Stephanie Brictson, Temple University
ClinicalTrials.gov Identifier:
NCT01068873
First received: February 12, 2010
Last updated: June 5, 2014
Last verified: June 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this pilot study is to assess the efficacy of lopinavir/ritonavir (Kaletra, a protease inhibitor, PI) when used in combination with maraviroc (Selzentry, an HIV entry inhibitor) for the treatment of antiretroviral naïve HIV infected patients. Twenty patients will be enrolled and studied for 48 weeks.
| Condition | Intervention | Phase |
|---|---|---|
| HIV Infections | Drug: lopinavir/ritonavir plus maraviroc | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Kaletra and Maraviroc in Antiretroviral Therapy-Naïve Patients - KALMAR Study -Version 1.0 Amendment 2 |
Resource links provided by NLM:
Further study details as provided by Stephanie Brictson, Temple University:
Primary Outcome Measures:
- Assess proportion of participants with HIV RNA levels <50 and < 400 copies/mL. [ Time Frame: week 48 ]
Secondary Outcome Measures:
- Assess proportion of participants with HIV RNA < 50 and <400 copies/ml. [ Time Frame: week 24 ]
- Assess the proportion of participants at study termination with VL < 50 copies/ml. [ Time Frame: week 48 ]
- Determine the time to viral suppression (VL < 50 copies/ml). [ Time Frame: 48 weeks ]
- Determine the median change in VL from baseline to week 24, to week 48 and to study termination. [ Time Frame: week 24, week 48 ]
- Assess the changes in CD4+ T cell count. [ Time Frame: week 24, 48 ]
- Assess development of HIV resistance mutations and in HIV co-receptor tropism changes in participants who develop virologic rebound. [ Time Frame: week 48 ]
- Assess safety and tolerability including any lipid changes. [ Time Frame: week 48 ]
| Enrollment: | 1 |
| Study Start Date: | April 2010 |
| Study Completion Date: | June 2014 |
| Primary Completion Date: | June 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: open label single arm
Drug: lopinavir/ritonavir plus maraviroc
|
Drug: lopinavir/ritonavir plus maraviroc
Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.
Other Names:
|
Detailed Description:
As patients with HIV are living longer it is important to explore antiretroviral treatments which may reduce the development of long term complications while preserving future HIV treatment options. This trial explores an antiretroviral treatment regimen which does not include the nucleoside reverse transcriptase inhibitor class which is thought to have long-term toxicity. This is a non-randomized, open label trial in participants meeting entry requirements.
Participants will be evaluated at screening, baseline,and weeks 4, 8, 12, 24, 36, and 48 to include clinical assessments as well as laboratory assessments.
An interim analysis will be performed when all patients have reached the week 24 visit.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- The patient has signed and dated approved informed consent form.
- There is confirmed laboratory diagnosis of HIV infection (positive ELISA HIV antibody test confirmed by Western blot, p24 antigen assay, quantitative HIV-1 RNA assay, or HIV culture).
- The patient is at least 18 years of age.
- ART-naïve, lopinavir/ritonavir susceptible on genotypic testing, CCR5-tropic virus on Trofile testing (ESTA).
- Negative pregnancy test within 72 hours prior to start of study for women of childbearing potential.
- Females of childbearing potential and males must utilize effective barrier contraception.
- HIV RNA greater than 1,000 copies per mL at entry.
- Liver enzymes (AST, ALT) < 3 times the upper limit of normal.
Exclusion Criteria:
- Patients who are pregnant or breast-feeding.
- Active alcohol or substance abuse sufficient, in the Investigator's opinion that makes compliance to the study protocol unlikely.
- Suspected or active HIV-related opportunistic infection or condition requiring acute therapy within 30 days of entry into the trial.
- Patients on therapy for hepatitis B.
- Patients with hepatitis B surface antigen, or any evidence of active hepatitis B such as positive hepatitis B DNA and/or presence of hepatitis e antigen or e antibody.
- Acute hepatitis B or C within 60 days of entry.
- Patients harboring preexistent co-receptor CXCR4 tropic or dual-or mixed-tropic HIV.
- Patients harboring HIV resistant to lopinavir/ritonavir on genotypic testing.
- The presence of decompensated heart failure, myocardial infarction within 1 year, bypass surgery, severe vascular disease, or active hepatobiliary disease.
- Concomitant use of rifampin, ergot derivatives (i.e. dihydroergotamine, ergotamine), cisapride, lovastatin, simvastatin, triazolam, orally administered midazolam, carbamazepine, phenytoin, St. John's wort, ketoconazole, itraconazole, clarithromycin, telithromycin, amiodarone, bepridil, flecainide, propafenone, quinidine, voriconazole or nefazodone.
- Patients with concomitant diagnosis of malignancy or cancer other than basal cell carcinoma within the past 5 years.
- Concomitant use of investigational agents including the use of any investigational vaccines.
- Any other clinical conditions or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for study, or unable to comply with the dosing requirements.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01068873
Please refer to this study by its ClinicalTrials.gov identifier: NCT01068873
Locations
| United States, Pennsylvania | |
| Temple General Internal Medicine | |
| Philadelphia, Pennsylvania, United States, 19140 | |
Sponsors and Collaborators
Temple University
Abbott
Pfizer
Investigators
| Principal Investigator: | Mary van den Berg-Wolf, MD | Temple University |
More Information
| Responsible Party: | Stephanie Brictson, Administrator, Temple University |
| ClinicalTrials.gov Identifier: | NCT01068873 History of Changes |
| Other Study ID Numbers: |
Temple IRB 12848 |
| Study First Received: | February 12, 2010 |
| Last Updated: | June 5, 2014 |
Keywords provided by Stephanie Brictson, Temple University:
|
HIV Protease Inhibitor CCR5 Co-receptor Antagonist treatment naive |
Additional relevant MeSH terms:
|
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Lopinavir Maraviroc |
HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors CCR5 Receptor Antagonists |
ClinicalTrials.gov processed this record on July 26, 2017